For the Inventor, By the Inventor

Enter assignee name

New Haven, CT, United States of America

Vion Pharmaceuticals, Inc.

USPTO Granted Patents = 17

CIPO Patents = 2

EPO Patents = 2

Trademarks = 2

Forward Citations = 447

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

David Gordon Bermudes (8 out of 58 patents)

Ivan C King (7 out of 8 patents)

Kenneth Brooks Low (6 out of 9 patents)

4. Terrence W Doyle (5 out of 47 patents)

5. Xu Kevin Lin (4 out of 6 patents)

6. Michael Belcourt (4 out of 4 patents)

7. Shu-Hui Chen (3 out of 17 patents)

8. Xiuyan Li (3 out of 3 patents)

9. Mario Sznol (2 out of 2 patents)

10. Caroline A Clairmont (2 out of 2 patents)

11. Jun Li (2 out of 2 patents)

12. Yung-Chi Cheng (1 out of 61 patents)

13. John Mao (1 out of 4 patents)

14. Yang Xu (1 out of 64 patents)

15. Li-Mou Zheng (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 7605137 - Combination therapy comprising cloretazine (2009-10-20),

2. 7514089 - Genetically modified tumor-targeted bacteria with reduced virulence (2009-04-07),

3. 7452531 - Compositions and methods for tumor-targeted delivery of effector molecules (2008-11-18),

4. 7405317 - Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents (2008-07-29),

5. 7354592 - Genetically modified tumor-targeted bacteria with reduced virulence (2008-04-08),

6. 7273714 - Alkylguanyltransferase assays (2007-09-25),

7. 6962696 - Compositions and methods for tumor-targeted delivery of effector molecules (2005-11-08),

8. 6923972 - Methods for use of genetically modified tumor-targeted bacteria with reduced virulence (2005-08-02),

9. 6911460 - Antiviral agents and methods of treating viral infections (2005-06-28),

10. 6863894 - Genetically modified tumor-targeted bacteria with reduced virulence (2005-03-08),

11. 6855695 - Water-soluble SHPs as novel alkylating agents (2005-02-15),

12. 6475482 - Genetically modified tumor-targeted bacteria with reduce virulence (2002-11-05),

13. 6458816 - Modified prodrug forms of AP/AMP (2002-10-01),

14. 6080849 - Genetically modified tumor-targeted bacteria with reduced virulence (2000-06-27),

15. 6005097 - Processes for high-yield diastereoselective synthesis of (1999-12-21),

Vion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative oncology drugs. With a strong focus on research and development, Vion Pharmaceuticals aims to provide targeted therapies for the treatment of various types of cancers. The company has a portfolio of promising drug candidates in different stages of clinical trials, with the goal of bringing effective and safe cancer treatments to patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#17 in New Haven, CT

#406 in Connecticut

#18,334 in US

#34,861 in the World

New Haven, CT, United States of America

Vion Pharmaceuticals, Inc.

Forward Citations = 447

23 inventors:

David Gordon Bermudes (8 out of 58 patents)

Ivan C King (7 out of 8 patents)

Kenneth Brooks Low (6 out of 9 patents)

4. Terrence W Doyle (5 out of 47 patents)

5. Xu Kevin Lin (4 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…